How Will Changing Trends Impact the Carbapenem-Based Antibiotics Market

Incidence of bacterial infections with multidrug resistance is increasing rapidly, generating the need for novel, broad-spectrum carbapenem-based antibiotics for the treatment of various bacterial infections. Broad-spectrum carbapenem-based antibiotics such as tebipenem (Spero Therapeutics Inc.) and sulopenem (Iterum Therapeutics Inc.) are at late stage clinical development with expected launch of both in 2020 – 2021.

For detailed insights on enhancing your product footprint, request for a sample here –

Multidrug resistance to currently marketed carbapenem-based antibiotics is largely prevalent in the world. Also, expiry of patent for ertapenem is expected to offer new avenues for market growth in regulated as well as non-regulated carbapenem-based antibiotics market where its adoption & availability are comparatively limited. On the back of these factors, the global carbapenem-based antibiotics market is estimated to reach a valuation of US$1.8 Bn by 2029.

Key Takeaways of Carbapenem-based Antibiotics Market Study

  • Larger patient pools and launch of novel products for the treatment of bacterial infections are expected to shape the carbapenem-based antibiotics market landscape.
  • Increasing prevalence of bacterial infections caused by longer stay in hospitals as well as immunocompromising chronic diseases that make patients prone to bacterial infections is expected to boost carbapenem-based antibiotics market growth.

For critical insights on this market, request for methodology here –

  • Currently, the carbapenem-based antibiotics market is dominated by ertapenem. However, tebipenem is expected to gain traction during the forecast period in terms of revenue.
  • In terms of indication, pneumonia is expected to garner highest market share as compared to other bacterial infections owing to a large patient pool.

“ Recently, FDA granted Qualified Infectious Disease Product (QIDP) to sulopenem as well as tebipenem for new indications, which is further expected to broaden the growth prospect of the carbapenem-based antibiotics market,” says the Fact.MR Analyst.

Strategic Expansion by Dominant Players Benefiting Market

The carbapenem-based antibiotics market is dominated by top three players including Merck Co. & Inc., Pfizer Inc., and Sumitomo Dainippon Pharma Co., Ltd. These leading players in the carbapenem-based antibiotics market contribute around 80% to 90% revenue share. Clinical stage companies such as Spero Therapeutic Inc. and Iterum Therapeutics Inc. with the launch of their novel carbapenem-based antibiotics are expected to acquire significant market space.

For in-depth competitive analysis, buy now –

In October 2017, Spero Therapeutics, Inc. and Meiji Seika Pharma Co., Ltd. announced an exclusive licensed partnership for its carbapenem-based antibiotic named SPR994 (tebipenem). In a similar development, Sumitomo Dainippon Pharma in June 2017, announced a partnership with Zuellig Pharma for sales of carbapenem-based antibiotic meropenem in five countries of Southeast Asia (Vietnam, Thailand, Singapore, Philippines, Malaysia) and Hong Kong.

Read More Trending and Similar Reports from Fact.MR –

Explore Fact.MR’s Comprehensive Coverage on Healthcare Landscape

Lung Management Products Market Forecast, Trend Analysis & Competition Tracking-Global Market Insights 2018 to 2028-

Primary Hyperoxaluria Treatment Market Forecast, Trend Analysis, & Competition Tracking – Global Market Insights 2020 to 2030-

Surgical AR Systems Market Forecast, Trend Analysis, & Competition Tracking – Global Review 2020 to 2030-

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.


US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Visit Our Website:

Leave a Reply

Your email address will not be published. Required fields are marked *